Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Phase III Trial of Leukine® Vs Neupogen® in Patients Receiving Cisplatin & Gemcitabine for Urothelial Cancer
This study has been terminated.
Study NCT00237575   Information provided by University of Kentucky
First Received: October 10, 2005   Last Updated: June 15, 2006   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Additional conditions recognized in this trial
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
gemcitabine
cisplatin
sargramostim
filgrastim
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
University of Kentucky
Bayer


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services